Synthesis, biological evaluation and preclinical study of a novel 99mTc-peptide: A targeting probe of amyloid-β plaques as a possible diagnostic agent for Alzheimer’s disease

• Published in: Bioorganic chemistry Vol. 99; p. 103857
• Main Authors: Jokar, Safura, Behnammanesh, Hossein, Erfani, Mostafa, Sharifzadeh, Mohammad, Gholami, Mahdi, Sabzevari, Omid, Amini, Mohsen, Geramifar, Parham, Hajiramezanali, Maliheh, Beiki, Davood
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.06.2020
• Subjects: Alzheimer’s disease; Cyclopentadienyl tricarbonyl; Radiopharmaceuticals; SPECT imaging; Technetium-99m; SPECT imaging; Alzheimer’s disease; Radiopharmaceuticals; Cyclopentadienyl tricarbonyl; Technetium-99m
• ISSN: 0045-2068; 1090-2120
• DOI: 10.1016/j.bioorg.2020.103857

[Display omitted] •Peptide targeting Aβ plaques was successfully synthesized.•Peptide radiolabeling was done by cyclopentadienyl tricarbonyl 99mTc precursor.•Biodistribution and imaging studies were done on Alzheimer's and normal rat models.•Autoradiography studies were applied on Alzheimer's and normal human brain sections.•99mTc-peptide could be a potential SPECT imaging agent for early detection of Aβ. With respect to the main role of amyloid-β (Aβ) plaques as one of the pathological hallmarks in the brain of Alzheimer’s patients, the development of new imaging probes for targeted detection of Aβ plaques has attracted considerable interests. In this study, a novel cyclopentadienyl tricarbonyl Technetium-99 m (99mTc) agent with peptide scaffold, 99mTc-Cp-GABA-D-(FPLIAIMA)-NH2, for binding to the Aβ plaques was designed and successfully synthesized using the Fmoc solid-phase peptide synthesis method. This radiopeptide revealed a good affinity for Aβ42 aggregations (Kd = 20 µM) in binding affinity study and this result was confirmed by binding to Aβ plaques in brain sections of human Alzheimer’s disease (AD) and rat models using in vitro autoradiography, fluorescent staining, and planar scintigraphy. Biodistribution studies of radiopeptide in AD and normal rats demonstrated a moderate initial brain uptake about 0.38 and 0.35% (ID/g) 2 min post-injection, respectively. Whereas, AD rats showed a notable retention time in the brain (0.23% ID/g at 30 min) in comparison with fast clearance in normal rat brains. Normal rats following treatment with cyclosporine A as a p-glycoprotein inhibitor showed a significant increase in the radiopeptide brain accumulation compared to non-treated ones. There was a good correlation between data gathered from single-photon emission computed tomography/computed tomography (SPECT/CT) imaging and biodistribution studies. Therefore, these findings showed that this novel radiopeptide could be a potential SPECT imaging agent for early detection of Aβ plaques in the brain of patients with AD.